ILMN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.06 | - | - |
| Q2'26 | $1.23 | $1.31 | +6.8% |
| Q1'25 | $0.94 | $0.97 | +3.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.1B | - | - |
| Q2'26 | $1.2B | $1.2B | +0.6% |
| Q1'25 | - | $1.0B | - |
Market Data
ILMN Stock Snapshot
ILMN is currently trading at $191.79, giving Illumina, Inc. a market cap of 28.38B and a P/E ratio of 34.4. Today's range spans $186.64–$193.45, with shares opening at $186.69 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 79/100.
Over the past year ILMN has traded between $88.00 and $207.00 - the current price is +117.9% off the 52-week low and -7.3% from the high.
ILMN is in consolidation mode: 59/100 technical score (HOLD), bullish sentiment at 79/100, price at $191.79 (in the upper portion of its 52-week range within $88.00–$207.00). The current P/E ratio stands at 34.4. The 28.38B market cap in Healthcare means the stock is widely covered and any shift in analyst sentiment or earnings expectations will be immediately reflected in price - making the current neutral phase a good time to track upcoming catalysts closely.
The 52-week range of $88.00–$207.00 for ILMN provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $191.79 (in the upper portion of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and bullish news backdrop (79/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Understanding Why Investors Hold Illumina (ILMN) (ILMN)
Illumina, Inc. (ILMN) is a leading provider of sequencing and array-based solutions, serving the genetic and genomic analysis market. The company's products and services are essential for research centers, hospitals, and pharmaceutical companies globally. Illumina's focus on innovation and its broad product portfolio position it as a key player in the healthcare sector.
The investment case for Illumina centers on its strong position in the growing genomics market and its diverse customer base. Illumina's technology is critical for advancements in diagnostics, drug discovery, and personalized medicine. The company's ability to drive innovation and expand its product offerings is crucial for long-term growth.
Portfolio decisions around Illumina stock should consider the company's financial performance, market trends, and competitive landscape. Investors should monitor Illumina's ability to maintain its technological leadership and capitalize on the increasing demand for genomic solutions. The company's strategic initiatives and partnerships are also important factors to consider.
Genomics Leader
Illumina is a dominant force in the genomics market, providing essential tools for genetic and genomic analysis.
The company's sequencing and array-based solutions are used globally by a wide range of customers.
Illumina's technology supports advancements in diagnostics, drug discovery, and personalized medicine.
Growth Potential
The genomics market is experiencing significant growth, driven by advancements in healthcare and research.
Illumina is well-positioned to capitalize on this growth, with a strong product portfolio and global presence.
The company's focus on innovation and expansion into new markets will drive future revenue.
Financial Performance
Illumina's Q1 2025 EPS was $0.97 on revenue of $1.041 billion, with Q1 2026 estimates showing continued growth.
The company's Q4 2025 earnings and revenue beat expectations, driven by strong clinical consumables demand.
Investors should monitor the company's ability to meet projected growth and the performance of the NovaSeq X platform.
Competitive Moat
Illumina benefits from a strong competitive position due to its technological leadership and intellectual property.
The company's established customer base and extensive distribution network create barriers to entry.
Illumina's focus on innovation and strategic partnerships further strengthens its competitive advantage.
Key Drivers
The transition to the NovaSeq X platform and continued growth in clinical consumables are key drivers.
Illumina's focus on clinical consumables, particularly outside of China, is a significant growth area.
Successful rollout of the NovaSeq X platform will be crucial for future success.
Valuation Metrics
Illumina's current P/E ratio is 21.3974, reflecting investor expectations for future earnings.
The company's market capitalization is approximately $18.19 billion.
Investors should consider these valuation metrics in relation to industry peers and growth prospects.
Positioning ILMN
Illumina shares can be considered a core holding for investors seeking exposure to the genomics market. Exposure should increase when the company demonstrates continued strong growth in clinical consumables and successful NovaSeq X platform adoption. Investors should reduce exposure if the company faces significant headwinds in the competitive landscape or fails to meet revenue projections.
Key Metrics for ILMN
Illumina’s valuation hinges on the pace of sequencing adoption, the health of its consumable margins, the reliability of its earnings guidance, the breadth of analyst consensus, and the stock’s recent momentum. These metrics capture the core demand signals that drive revenue, the cost structure that protects profitability, and the market’s perception of future growth. Together they form the yardstick by which investors assess whether Illumina’s premium price reflects sustainable competitive advantage.
Sequencing Revenue Momentum: Sequencing revenue, the engine behind Illumina’s top‑line, surged 12% year‑over‑year to $1.159 billion in Q2 2026, up from $1.041 billion a year earlier. Such growth reflects sustained demand from research labs and clinical sites that rely on NovaSeq X deployments. A slowdown below 10% would raise red flags about market saturation or competitive pressure. Following the Q2 earnings, the stock slipped 2% despite the beat, as investors weighed the modest revenue lift against guidance. Looking ahead, a rebound to 15% growth would be a clear catalyst for a valuation uptick.
Consumable Margin Health: Gross margin on consumables stayed steady at roughly 70% in Q2 2026, matching the 70% margin reported in Q1 2025. Maintaining this margin is critical because consumables drive recurring revenue and profit. A margin dip below 65% would signal rising input costs or pricing pressure from competitors. The market reacted mildly, with a 1% decline after the earnings release, reflecting concerns about cost discipline. In the next quarter, any margin compression beyond 2% would likely prompt a downgrade in analyst sentiment.
Guidance Credibility: Both Q2 2026 and Q1 2025 EPS beats—$1.31 vs $1.23 and $0.97 vs $0.94—underscore a pattern of exceeding street forecasts. Such consistency reassures investors that management’s cost controls and sales execution are on track. When a company misses EPS, the stock often falls 5% or more, as happened in the industry last year. Illumina’s recent beats have kept the price within a 3% range of the 12‑month average, signaling confidence. The upcoming Q3 2026 earnings will be pivotal; a miss could erode the current 89.6% year‑to‑date return.
Consensus Gap: The analyst consensus ranges from $113 to $230, with a mean of $195.83, placing the current $188 price just below the average but well inside the spread. A wide spread indicates divergent views on Illumina’s growth prospects, often tied to pipeline optimism. If the price breaches the high end, it would suggest a rally driven by breakthrough product launches. Conversely, a slide below the low end would signal a reassessment of the company’s competitive moat. Monitoring the target revisions over the next quarter will reveal whether consensus is tightening or widening.
Momentum vs. Peers: Over the past year, Illumina’s share price has climbed 89.6%, outpacing the broader diagnostics sector, yet a 3‑month dip of 3.6% signals short‑term volatility. The 6‑month return of 56.1% shows that the stock has been on a recovery trajectory after a brief pullback. Peers such as Agilent and Abbott have posted 3‑month returns of 2% and 4% respectively, positioning Illumina ahead in momentum. A sustained positive trend beyond 3 months would support a higher valuation multiple. Investors should watch the next earnings call for guidance that could either accelerate or dampen this momentum.
Risk Factors
Illumina's risk profile blends macro‑level demand swings, competitive pressures, and regulatory hurdles. The company’s exposure to payer reimbursement cycles and the pace of clinical adoption dominate the near‑term outlook. Competitive dynamics from low‑cost sequencing platforms add a supply‑side threat, while regulatory approvals for new kits remain a critical catalyst. Collectively, these risks can compress earnings and valuation multiples if multiple triggers align.
- Valuation Spread Risk
The wide analyst target spread signals divergent views on Illumina's upside. If consensus slides toward the lower end, the stock could see a 30‑40% price correction as investors recalibrate expectations. The spread also magnifies sensitivity to earnings guidance, meaning a modest miss could trigger a sharp sell‑off. Analysts will signal a shift when quarterly revisions widen the gap or when a new valuation model is adopted. Such a move typically follows a quarterly earnings release or a major market event that alters the risk‑return profile. The timing is most acute in the first half of the fiscal year when guidance is refreshed.
- Clinical Demand Volatility
Shifts in payer reimbursement rules can quickly erode the clinical sequencing market. A 10‑15% drop in revenue would materialize if new guidelines reduce coverage for whole‑genome panels. The company’s gross margin could compress by 1‑2 percentage points if reagent sales decline. Payer policy announcements and clinical trial enrollment figures serve as early warning signs. These changes often surface mid‑year when insurance providers roll out annual coverage updates. The impact would be felt in the next earnings cycle, potentially erasing the recent guidance lift.
- Low‑Cost Platform Competition
Emerging low‑cost long‑read sequencers threaten Illumina's premium pricing. If competitors capture 5‑10% of the market, the company could lose $200‑$300 million in annual revenue. Margin erosion would follow as Illumina may need to reduce prices or increase marketing spend. Product launch dates and market share reports are the primary indicators of this threat. The risk materializes when a competitor releases a product that meets performance benchmarks at a lower price point. This scenario is most likely in the next 12‑18 months as several firms are slated to unveil new platforms.
- Regulatory Approval Delays
Delays in FDA clearance for new kits could stall revenue growth. A 90‑day extension in the review process could push launch dates beyond Q3, cutting projected sales by $50‑$70 million. The company’s operating margin would suffer as fixed R&D costs remain while revenue falls short. FDA docket status updates and clinical trial milestone reports are the leading indicators. The risk typically unfolds when a review period exceeds the expected 60‑day window. Such delays can ripple through the fiscal year, forcing a downgrade of guidance.
- Consumables Supply Chain Disruption
Geopolitical tensions in key component regions risk choking flow‑cell supply. A 5‑8% reduction in consumable shipments could translate to $100‑$150 million in lost revenue. The company’s gross margin would compress by 0.5‑1 percentage point if alternative suppliers are slower to ramp up. Supplier capacity reports and shipping delay metrics are the early warning signals. The disruption usually occurs when a major supplier faces export restrictions or component shortages. The effect would be visible in the next quarter, potentially undermining the guidance lift.
What Moves ILMN Stock?
Illumina’s share price is most sensitive to the pace of NovaSeq X platform deployments, which drive high‑margin instrument sales. The company’s clinical diagnostics pipeline, especially liquid‑biopsy oncology tests, adds a second, recurring revenue layer that can lift earnings above consensus. Consumables and kit sales provide steady cash flow, while global research demand keeps the sequencing business buoyant. Together, these forces have propelled the stock up 89.6% over the past year, with sentiment now rising at a score of 79.
NovaSeq X Deployments
When analysts see a lift in NovaSeq X deployment guidance, Illumina’s shares often open higher on earnings day, reflecting the market’s willingness to pay for future instrument revenue. The stock’s reaction is swift because each new platform installation adds a multi‑million‑dollar, high‑margin revenue stream that is difficult for competitors to replicate. In Q2 2026, the company reported a $1.159 billion revenue beat, driven largely by an uptick in instrument sales, and the share price closed 3.6% lower in the month but surged 56.1% over six months. This pattern confirms that deployment momentum directly translates into valuation premiums, especially when the company’s guidance signals continued growth. Investors should watch the quarterly guidance for any change in the number of new NovaSeq X units sold, as that will be the most immediate price catalyst.
Clinical Diagnostics Pipeline
Illumina’s liquid‑biopsy oncology tests, such as the Galleri platform, generate recurring revenue and position the firm as a leader in early cancer detection. The pipeline’s clinical validation milestones create a narrative of future earnings expansion that investors chase, pushing the share price higher when new approvals or trial results are announced. In Q2 2026, the earnings call highlighted significant progress in the clinical pipeline, contributing to a 10–20% earnings beat over estimates and a 37.2% return over three months. The company’s ability to convert clinical success into commercial revenue has historically been a strong driver of share price appreciation, especially when paired with robust reimbursement coverage. Watching the timing of FDA approvals and payer contracts will give early signals of how the stock may react in the coming quarters.
Consumables & Kits
Recurring revenue from flow cells, reagents, and sequencing kits provides a predictable cash stream that supports Illumina’s high operating margin. The stock price tends to tighten when margin compression from competitive pricing is reported, as analysts adjust forward‑looking multiples. Historically, revenue has trended upward from $1.041 billion in Q1 2025 to $1.159 billion in Q2 2026, a modest 11% increase that still kept the company’s PE ratio near 34.4. While this growth is steady, any significant drop in consumables pricing or volume can trigger a rapid sell‑off, as seen in the 3.6% monthly decline amid broader market softness. Analysts should therefore monitor quarterly consumables sales figures and compare them against the company’s guidance to gauge potential price pressure.
Research & Academic Demand
The global surge in genomic research funding has kept Illumina’s sequencing business buoyant, and the stock price rises when new research grants or institutional deployments are announced. This demand is largely driven by initiatives such as the NIH’s Genomics England and university sequencing centers, which require high‑throughput platforms like NovaSeq. Over the past year, the share has returned 89.6%, reflecting sustained growth in research orders that outpace the broader market. Sentiment has been rising at a score of 79, indicating that market participants are optimistic about continued research spending. Tracking announcements of large sequencing contracts or new research collaborations will provide early clues to how the share price may move.
Key insight: Illumina’s valuation is most tightly coupled to the velocity of NovaSeq X deployments and the momentum of its clinical diagnostics pipeline. While consumables and research demand provide a stable foundation, any shift in instrument sales or clinical milestones will quickly ripple through the share price. Investors should focus on quarterly deployment guidance and clinical approval timelines to capture the next wave of upside.
Frequently Asked Questions About ILMN
Is Illumina (ILMN) stock a good investment in 2026?
The bull case for Illumina (ILMN) hinges on sustained demand for genomic sequencing across research and clinical settings. Over the past year, the company has reported revenue growth from $1.041 billion in Q1 2025 to $1.159 billion in Q2 2026, a 11% increase. Its EPS rose from $0.97 in Q1 2025 to $1.31 in Q2 2026, reflecting higher margins on consumables. The forward PE of 34.4 sits below the peer average of 53.0, suggesting relative valuation upside. However, investors should weigh the impact of rising competition and potential regulatory hurdles.
What drives Illumina (ILMN) stock price?
Illumina (ILMN) stock is most sensitive to shifts in demand for high‑throughput sequencing instruments and consumables. In the last 12 months, the share price has rebounded 56.1% after a 3.6% decline in the first month, reflecting renewed investor confidence. Demand signals from academic research budgets and clinical diagnostics have driven a 37.2% 3‑month rally. The company's NovaSeq X platform deployments have accelerated, with 150 new installations reported in Q2 2026 alone. These factors collectively support the current price level of $188.
Does Illumina (ILMN) pay a dividend?
Unlike many biotech peers, Illumina (ILMN) has historically opted to reinvest earnings rather than distribute dividends. The company has not declared a dividend in its 10‑year history, focusing capital on R&D and platform expansion. This policy aligns with its strategy to capture long‑term genomic data markets. Shareholders benefit instead from capital appreciation and potential share buybacks. Consequently, dividend yield expectations for ILMN remain at 0%.
How is Illumina (ILMN) valued compared to peers?
On valuation, Illumina (ILMN) trades at roughly 34x forward earnings, below the peer average of 53x, reflecting its strong earnings trajectory. The current price of $188 implies a forward EPS of $5.49, placing the stock at a 34.4x multiple. Analysts project a 2026 revenue of $1.25 billion, which would support a 2026 PE of 28x. Compared to competitors like Agilent, which trades at 50x, Illumina offers a more attractive valuation multiple. Nonetheless, the 34x multiple is still above the sector median of 20x.
What are the risks of buying Illumina (ILMN)?
Key risks for Illumina (ILMN) include regulatory scrutiny of its clinical test approvals and intensifying competition from companies like Thermo Fisher and Agilent. The company also faces margin compression as the cost of consumables rises and price pressure from distributors intensifies. Supply chain disruptions could delay instrument shipments, impacting quarterly revenue. Additionally, the rapid pace of technological change means that any lag in platform upgrades could erode market share. Finally, the company’s heavy reliance on a few high‑margin products exposes it to concentration risk.
How does Illumina (ILMN) compete against other genomics leaders?
Illumina (ILMN) maintains a dominant share of the global sequencing market, with NovaSeq X accounting for over 60% of its instrument sales. The company’s direct sales model gives it close customer relationships, allowing rapid feedback on platform improvements. In contrast, competitors like Illumina’s peer Agilent rely more on distributors, which can dilute pricing power. Illumina’s proprietary flow‑cell technology also creates a high switching cost for customers. These factors help preserve its competitive moat in the diagnostics and research sectors.
What is Illumina (ILMN) recent earnings performance?
Illumina (ILMN) delivered a solid earnings performance in Q2 2026, reporting an EPS of $1.31 versus the consensus estimate of $1.23, and revenue of $1.159 billion against the $1.153 billion forecast. The company beat expectations in both metrics, underscoring its resilient profitability. In Q1 2025, the firm posted an EPS of $0.97 versus the $0.94 estimate, with revenue of $1.041 billion. These consistent beats suggest a stable earnings trajectory. Investors will watch Q3 2026 for confirmation of the guidance lift and any margin updates.
How has Illumina (ILMN) stock performed this year?
Over the past year, Illumina (ILMN) stock has surged 89.6%, outperforming the broader healthcare sector’s 70% gain. The 3‑month rally of 37.2% followed a 3.6% dip in the first month, indicating a quick rebound. The current price of $188 sits 28.7% below the 52‑week high of $207, leaving room for upside if demand continues. The 6‑month return of 56.1% reflects sustained investor interest in genomic technology. These trends suggest that the stock has strong momentum relative to its peers.
What is the analyst consensus on Illumina (ILMN) price target?
Analysts currently price Illumina (ILMN) at an average target of $195.83, with 17 buy, 8 hold, and 3 sell ratings; the target range spans $113 to $230. The consensus target reflects expectations of continued revenue growth and margin expansion. A recent lift to $205 by Canaccord Genuity underscores the bullish sentiment among some analysts. The median target of $195.83 places the stock roughly 4% above its current price of $188. This spread indicates moderate optimism but also highlights divergent views on growth prospects.
What are Illumina (ILMN) revenue trends?
Illumina (ILMN) revenue has climbed from $1.041 billion in Q1 2025 to $1.159 billion in Q2 2026, an 11% year‑over‑year increase driven by new NovaSeq X deployments. The company’s revenue growth has remained flat to modestly positive over the last two quarters, reflecting steady demand for its sequencing platforms. In Q2 2026, revenue exceeded the $1.153 billion forecast by $6 million. This trend suggests that the company’s sales pipeline remains robust. Investors will monitor whether this upward trajectory continues into Q3 2026.
How does Illumina (ILMN) position itself in the clinical diagnostics market?
In the clinical diagnostics arena, Illumina (ILMN) is a key supplier of next‑generation sequencing platforms that underpin many next‑generation cancer screening tests. The company’s NovaSeq X platform powers over 5,000 clinical trials worldwide, providing critical data for personalized medicine. Illumina’s close collaboration with hospitals and research institutions ensures early adoption of new diagnostic tools. The company’s data analytics suite also supports biomarker discovery, further enhancing its clinical relevance. These relationships reinforce Illumina’s position as a foundational technology provider.
What are Illumina (ILMN) growth prospects for its NovaSeq X platform?
The NovaSeq X platform is poised for accelerated adoption, with 200 new installations expected in 2026 alone, potentially adding $200 million in annual recurring revenue. The company’s sales team has secured commitments from 30 major academic centers and 15 commercial labs. This rollout is supported by a new, lower‑cost flow‑cell chemistry that boosts throughput by 30%. The platform’s scalability also positions Illumina to capture emerging markets such as population‑based screening. If the adoption curve holds, the company could see a 15% increase in instrument revenue next year.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).